GLP-1 RAs (Semaglutide , Liraglutide) GLP-1 RAs are generally well tolerated, though gastrointestinal side effects, especially nausea, vomiting, and diarrhea, are common, particularly during dose escalation
As a result, people are eating 700 calories less than they normally would
Whether shown by a ten-fold, four-fold, five-fold, or 19% increase, studies have consistently reported a higher likelihood of GLP-1 RA users having more residual gastric contents, even after appropriate fasting, compared to non-users (Critical appraisal skills programme 2026
It is no wonder that the recent rise of GLP-1 receptor agonists, such as semaglutide and tirzepatide, has sparked significant interest
It may take time to convince payers, but it will happen